Evidence map›Paper›PMID 22869581›Full record

Trial reportAntimicrobial agents and chemotherapy2012

Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia.

David Saunders, Phisit Khemawoot, Pattaraporn Vanachayangkul, Raveewan Siripokasupkul, Delia Bethell, Stuart Tyner, Youry Se, Wiriya Rutvisuttinunt, Sabaithip Sriwichai, Lon Chanthap and 8 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Antimalarial Potency ofJournal of tropical medicine · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Clinical microbiology reviews · 2019
    Review
  14. Article
  15. Artemisinin resistance phenotypes and K13 inheritance in aProceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 5 countries.

David SaundersDepartment of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand. david.saunders@afrims.org
Phisit Khemawoot
Pattaraporn Vanachayangkul
Raveewan Siripokasupkul
Delia Bethell
Stuart Tyner
Youry Se
Wiriya Rutvisuttinunt
Sabaithip Sriwichai
Lon Chanthap
Jessica Lin
Ans Timmermans
Doung Socheat
Pascal Ringwald
Harald Noedl
Bryan Smith
Mark Fukuda
Paktiya Teja-Isavadharm
Armed Forces Research Institute of Medical Science · THArmed Forces Health Surveillance Center · USCambodia National Malaria Center · KHChulalongkorn University · THMedical University of Vienna · ATUnited States Army Medical Research and Development Command · USUniversity of North Carolina at Chapel Hill · USWorld Health Organization · CH

Funding

STANFORD COMPOSITE(RMI)U54HG004028 · NHGRI · STANFORD UNIVERSITY · PI MUSEN, MARK A · 2005 to 2014
$36.2M
NHGRI NIH HHS U54 HG004028
6 · The paper itself

Abstract

Artemisinin-resistant malaria along the Thailand-Cambodian border is an important public health concern, yet mechanisms of drug action and their contributions to the development of resistance are poorly understood. The pharmacokinetics and pharmacodynamics of oral artesunate monotherapy were explored in a dose-ranging trial in an area of emerging artesunate resistance in western Cambodia. We enrolled 143 evaluable subjects with uncomplicated Plasmodium falciparum malaria in an open label study of directly observed artesunate monotherapy at 3 dose levels (2, 4, and 6 mg/kg of body weight/day) for 7 days at Tasanh Health Center, Tasanh, Cambodia. Clinical outcomes were similar among the 3 groups. Wide variability in artesunate and dihydroartemisinin concentrations in plasma was observed. No significant dose-effect or concentration-effect relationships between pharmacokinetic (PK) and parasite clearance parameters were observed, though baseline parasitemia was modestly correlated with increased parasite clearance times. The overall parasite clearance times were prolonged compared with the clearance times in a previous study at this site in 2006 to 2007, but this did not persist when the evaluation was limited to subjects with a comparable artesunate dose (4 mg/kg/day) and baseline parasitemia from the two studies. Reduced plasma drug levels with higher presentation parasitemias, previously hypothesized to result from partitioning into infected red blood cells, was not observed in this population with uncomplicated malaria. Neither in vitro parasite susceptibility nor plasma drug concentrations appeared to have a direct relationship with the pharmacodynamic (PD) effects of oral artesunate on malaria parasites. While direct concentration-effect relationships were not found, it remains possible that a population PK modeling approach that allows modeling of greater dose separation might discern more-subtle relationships.

Indexed as

Administration, OralAdultAntimalarialsArtemisininsArtesunateCambodiaDrug Administration ScheduleFemaleHumansMalaria, FalciparumMaleParasitemiaPlasmodium falciparumSeverity of Illness IndexAntimalarialsArtemisininsartenimolArtesunate

Identifiers

PMID22869581
PMCPMC3486599
OpenAlexW2167053896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.